Livin和Smac蛋白在非霍奇金淋巴瘤中的表达及其临床意义

 目的　研究抗凋亡蛋白Livin和促凋亡因子Smac在非霍奇金淋巴瘤（NHL）中的表达及其与临床特征和预后间的关系。方法　应用免疫组织化学方法检测31例NHL患者Livin和Smac表达情况，并将其与临床随访进行临床特征和生存预后关系的研究。 结果　Livin蛋白高表达的患者多为有B症状、Ⅲ／Ⅳ期和国际预后指数（IPI）高危者，而Smac蛋白高表达患者多为无症状、Ⅰ／Ⅱ期和IPI低危者。但Livin和Smac蛋白表达均与性别和年龄无相关关系。Livin和Smac两者之间无相关关系（r＝0.003，P＞0.05）。Livin蛋白低表达患者的生存情况明显好于高表达患者，而Smac蛋白高表达的生存情况明显好于低表达患者。结论　Livin表达与NHL不良临床特征及预后相关，而Smac表达与良好的临床特征及预后有关。

The expression and clinical significance of Livin and Smac in patients with non-Hodgkin lymphoma

Objective To study the expression and clinical significance of Livin ( anti-apoptosis protein) and Smac (promoting apoptosis factor) in patients with the non-Hodgkin lymphoma (NHL).Methods The expression of Livin and Smac were detected by immunohistochemical staining(SP) assay in 31 patients with NHL, and the relationship between Livin/Smac and clinical staging, IPI and prognosis were analyzed. Results The patients with positive expression of Livin had B symptom, high risk IPI, late clinical staging (Ⅲ/Ⅳ stage) and short survival time, while the ones with positive expression of Smac had no B symptom, early clinical staging( Ⅰ /Ⅱ stage), low risk IPI and good prognosis. The expressions of both Livin and Smac were not related to gender and age. Expression of Livin was not correlated to that of Smac (r =0.003,P ＞0.05). Conclusion For patients with NHL, the expression of Livin protein was related to poor prognosis and adverse clinical features, whereas the expression of Smac protein was related to good prognosis and clinical feature.